Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 December;108(6) > Minerva Medica 2017 December;108(6):502-6



Publication history
Cite this article as


A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878




Minerva Medica 2017 December;108(6):502-6

DOI: 10.23736/S0026-4806.17.05252-1


language: English

Idiopathic thrombocytopenic purpura: pathogenesis and potential therapeutic approach

Xiaohong ZHAO, Xiaomei QI, Chen WANG, Zhonghao ZHOU, Haiwu CAO, Pin WU, Linghao LI, Shiyun LU, Zhi WANG

Department of Hematology, Wuxi Second People’s Hospital, Nanjing Medical University, Wuxi, China


BACKGROUND: This study sought to clarify the pathogenesis of idiopathic thrombocytopenic purpura (ITP) and make preliminary investigations regarding a therapeutic approach.
METHODS: Enzyme-linked immunosorbent assay was used to establish and analyze the standard curve for interferon (IFN) γ, interleukin (IL) 4, and IL-17 in order to determine a measurement method for these cytokines. Subsequently, cellular levels of IFN-γ, IL-4, and IL-17 in the peripheral blood of patients in the treatment group (traditional Chinese medicine) was compared with those in the control group (Western-style care). An ITP mice model was also established and treated with different medications.
RESULTS: Th1/Th2 cell quantities in ITP patients were significantly higher than in healthy individuals (P<0.05). Furthermore, IL-17 secreted by Th17 cells was significantly higher in ITP patients than healthy individuals (P<0.01). A combination of traditional Chinese medicine and Western-style care yielded the best treatment effect for ITP mice, followed by Western medicine alone and then Chinese medicine alone.
CONCLUSIONS: The experimental results suggested that Th17 cells may be more related to the pathogenesis of ITP, and that application of Western-style care supplemented by traditional Chinese medicine may yield a more optimal treatment for ITP.

KEY WORDS: Idiopathic thrombocytopenic purpura - Etiology - Therapeutics

top of page

Publication History

Issue published online: November 2, 2017
Article first published online: June 21, 2017
Manuscript accepted: May 25, 2017
Manuscript received: May 10, 2017

Cite this article as

Zhao X, Qi X, Wang C, Zhou Z, Cao H, Wu P, et al. Idiopathic thrombocytopenic purpura: pathogenesis and potential therapeutic approach. Minerva Med 2017;108:502-6. DOI: 10.23736/S0026-4806.17.05252-1

Corresponding author e-mail